Recruitment

Recruitment Status
Completed
Estimated Enrollment
282

Exclusion Criterias

use of corticosteroids for at least 30 days in the last 6 months
Active infection or inflammation in any eye
Pregnant or nursing women or women of child bearing potential without unless using an effective contraception
...
use of corticosteroids for at least 30 days in the last 6 months
Active infection or inflammation in any eye
Pregnant or nursing women or women of child bearing potential without unless using an effective contraception
Stroke or myocard infarction within 3 months prior to study
treatment with anti-angiogenic drugs in any eye within last 3 months
Uncontrolled hypertension
Panretinal or focal/drid laser photocoagulation within the last few months
History of malignancy within the past 5 years

Summary

Conditions
Macular Edema Secondary to Branch Retinal Vein Occlusion
Type
Interventional
Phase
Phase 3
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Participant, Outcomes Assessor)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Exclusion Criterias

use of corticosteroids for at least 30 days in the last 6 months
Active infection or inflammation in any eye
Pregnant or nursing women or women of child bearing potential without unless using an effective contraception
...
use of corticosteroids for at least 30 days in the last 6 months
Active infection or inflammation in any eye
Pregnant or nursing women or women of child bearing potential without unless using an effective contraception
Stroke or myocard infarction within 3 months prior to study
treatment with anti-angiogenic drugs in any eye within last 3 months
Uncontrolled hypertension
Panretinal or focal/drid laser photocoagulation within the last few months
History of malignancy within the past 5 years

Locations

San Juan City, 1500
Beijing, 100034
Beijing, Beijing, 100191
Tianjin, Tianjin, 300070
Nanjing, Jiangsu, 210006
...
San Juan City, 1500
Beijing, 100034
Beijing, Beijing, 100191
Tianjin, Tianjin, 300070
Nanjing, Jiangsu, 210006
Wuhan, Hubei, 430070
Chengdu, Sichuan, 610041
Beijing, 100176
Harbin, Heilongjiang, 150001
Nanjing, Jiangsu, 210029
Hanoi, 10000
Beijing, Beijing, 100730
Tianjin, Tianjin, 300020
Changsha, Hunan, 410011
Jakarta, 10430
Ho Chi Minh City, 70000
Nanchang, Jiangxi, 330006
Chongqing, Chongqing, 400042
Beijing, 100730
Wenzhou, Zhejiang, 325027
Kaohsiung, 83301
Nantong, Jiangsu, 226000
Taipei
Bandung, Jawa Barat, 40117
Shanghai, 200092
Lin-Kou, 33305
Chongqing, 400038
Hongkong
Guangzhou, Guangdong, 510060
Qingdao, Shandong, 266011
Manila, Metro Manila, 1000
Shantou, Guangdong, 515041
Shanghai, 200080

Tracking Information

NCT #
NCT01976338
Collaborators
Not Provided
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals